Hedge Fund Chief Shkreli Juggles Ire for Biotech Missteps With Passion For Rare-Disease Startup Retrophin

4/3/12Follow @arleneweintraub

(Page 2 of 4)

clinical-trial program in excruciating detail, comparing it with that of other companies pursuing cell therapies, before coming to a rather blunt conclusion: “Despite some diehard faith from Cytori investors and seemingly, management, there is limited clinical proof of concept for Cytori’s approach.”

Tom Baker, Cytori’s director of investor relations, isn’t amused. “I wonder how one could so summarily dismiss an entire field,” he says. “We’re very bullish on the whole stem cell sector. We don’t dwell on someone’s doubts.”

Some of Shkreli’s sparring has extended far beyond his blog posts, however. On Christmas Day 2010, Shkreli wrote a letter to 10 FDA officials urging them to reject an inhaled insulin product made by MannKind (NASDAQ: MKND), a Valencia, CA-based company founded by billionaire octogenarian and medical-device veteran Al Mann. A few weeks later, at the JP Morgan Healthcare Conference in San Francisco, Shkreli went to an investors’ meeting led by Mann and “asked a lot of questions that I think annoyed him,” Shkreli says.

Shkreli’s main problem with the product, he says, was “a very, very deficient clinical trial program.” Specifically, he says, the company redesigned the inhaler but didn’t run trials to prove it worked.

On January 20 of this year, the FDA issued a “complete response” letter to MannKind, requesting that the company run two trials of the new inhaler. The company’s stock has lost half its value in the past year and has been trading recently at about $2.45.

And yes, Shkreli freely admits he was shorting MannKind’s stock at the time of his battle with the company. “I thought it was important to bring attention to this idea that the company hadn’t done its trials in the way it should have. So I shorted the stock and made my position clear,” Shkreli says. “I think the short is one of the greatest investments we’ve ever made.”

MannKind declined to comment.

A more recent FDA correspondence has gotten Shkreli in hot water with a Washington, DC, outfit called Citizens for Responsibility and Ethics in Washington (CREW). After blasting Dublin, OH-based Neoprobe (AMEX: NEOP) in four Seeking Alpha postings, Shkreli wrote a petition to the FDA last June requesting that the agency not consider approving the company’s product, which is a radioactive agent used to detect lymph nodes. Shkreli suggested that the FDA should require the company to test its drug against another radioactive product that’s currently used in combination with blue dye for lymph node mapping.

On January 26, after months of collecting supporting documents from the FDA—and some from Shkreli himself—CREW sent a letter to the SEC asking the commission to open an investigation into Shkreli’s short-selling activities. The 60-page letter includes multiple examples of Shkreli’s correspondences with the FDA, and requests that the SEC require Shkreli to disclose MSMB’s holdings. CREW suggests in its letter that the SEC then compare Shkreli’s trading patterns with his attempts “to influence the outcome of the FDA’s approval process.”

Anne Weismann, chief counsel for CREW, says in an interview with Xconomy that her organization isn’t alleging Shkreli engaged in collusion, but rather demanding further investigation into his trading activities. “With hedge funds, there’s limited information publicly available,” Weismann says. Comparisons of Shkreli’s FDA petitions to his trades “should be done by someone who has greater access than we do.”

Shkreli was more than happy to help CREW with its investigation, sending the organization copies of some of his FDA correspondences, all the while contending that shorting stocks is … Next Page »

Single Page Currently on Page: 1 2 3 4 previous page

By posting a comment, you agree to our terms and conditions.

  • http://yahoo.com dale platt

    Shkreli should be incarcerated for trying to manipulate the FDA.

    He should also take handwriting lessons. Have you seen his personal signature! It looks like something a 2nd grader would sign.

  • Robin

    I’ve got an idea: Let’s SHORT this psychopathic, clown’s Retrophin.

    Taste of his own medicine should be good for him and divine retribution for all the desperate diabetics who were hoping Afrezza would have come to market by now.

    Shrekeli may be smart, but if one uses that genius to deliberately harm companies, break the bank accounts of innocent shareholders, and keep vital therapies away from people who need them then you’re the worst human on the planet.

  • Rich

    Marty Shkreli is pathetic. Anyone that would associate themselves with this person has to be questioned based on the pathetic and bad manipulating things he’s done out of greed and selfishness. He’s not to be trusted from what I’ve seen and I believe he’s up to no good yet again! A shame!!

  • Eric

    The pipeline for Retrophin contains the dumbest ideas I have come across in the biotech industry. Trying to deliver recombinant dystrophin to the right subcellular localization in muscle is a pie in the sky. First of all dystrophin is one of the largest proteins known (>400kDa). Trying to deliver that into a cell is like a person trying to swallow a basketball-sized T-bone steak. I’m guessing they’ll try to bilk some ignorant investor on the virtues of the drug by showing that they can deliver this protein to damaged muscle cells. Little will these people know that damaged muscle cells will take up pretty much anything.

    DARA for FSGS? WTF?!? You do not want protein to be excreted in your urine. That is a clear sign of kidney diseseae. This drug is going to increase protein clearance in the kidney?!?!

  • Duke Layton

    hilarious how martin is ripped apart. the service he provides to the imbeciles who invest in the companies he shorts is invaluable but they ignore him. the ONTY dopes are particularly funny. and what’s wrong with voicing an opposing opinion when asses like brozak are spewing egregiously deficient “research”.

    and by the way, i’m not martin. i wish i were.

  • Pingback: Retrophin, Headed by Controversial Hedge Fund Chief, Raises $4M | Xconomy

  • Pingback: Shkreli’s Retrophin Makes Hostile Bid For CA-based Transcept | Xconomy

  • Pingback: The Capitals™ – Capitalists' Magazine | 資本家札記 | Shkreli’s Retrophin Makes Hostile Bid For CA-based Transcept

  • Pingback: Retrophin Shares Boom Following Manchester Pharma Buyout | Xconomy

  • Pingback: Retrophin Shares Boom Following Manchester Pharma Buyout | My Website